AU2019403057B2 - Therapeutic uses of gene edited fibroblasts - Google Patents

Therapeutic uses of gene edited fibroblasts

Info

Publication number
AU2019403057B2
AU2019403057B2 AU2019403057A AU2019403057A AU2019403057B2 AU 2019403057 B2 AU2019403057 B2 AU 2019403057B2 AU 2019403057 A AU2019403057 A AU 2019403057A AU 2019403057 A AU2019403057 A AU 2019403057A AU 2019403057 B2 AU2019403057 B2 AU 2019403057B2
Authority
AU
Australia
Prior art keywords
syndrome
disease
autoimmune
cells
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019403057A
Other languages
English (en)
Other versions
AU2019403057A1 (en
Inventor
Thomas Ichim
Pete O'HEERON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spinalcyte LLC
Original Assignee
Spinalcyte LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spinalcyte LLC filed Critical Spinalcyte LLC
Publication of AU2019403057A1 publication Critical patent/AU2019403057A1/en
Application granted granted Critical
Publication of AU2019403057B2 publication Critical patent/AU2019403057B2/en
Assigned to SPINALCYTE LLC reassignment SPINALCYTE LLC Request for Assignment Assignors: FIGENE, LLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2019403057A 2018-12-16 2019-12-16 Therapeutic uses of gene edited fibroblasts Active AU2019403057B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862780289P 2018-12-16 2018-12-16
US62/780,289 2018-12-16
PCT/US2019/066575 WO2020131717A1 (en) 2018-12-16 2019-12-16 Therapeutic uses of gene edited fibroblasts

Publications (2)

Publication Number Publication Date
AU2019403057A1 AU2019403057A1 (en) 2021-07-29
AU2019403057B2 true AU2019403057B2 (en) 2026-01-29

Family

ID=71102289

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019403057A Active AU2019403057B2 (en) 2018-12-16 2019-12-16 Therapeutic uses of gene edited fibroblasts

Country Status (6)

Country Link
US (1) US20220025332A1 (enExample)
EP (1) EP3894546A4 (enExample)
JP (2) JP2022513490A (enExample)
AU (1) AU2019403057B2 (enExample)
CA (1) CA3123408A1 (enExample)
WO (1) WO2020131717A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109837250B (zh) * 2019-01-15 2021-10-12 中国农业科学院兰州兽医研究所 羔羊睾丸支持细胞永生化细胞系及其建立方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165177A1 (en) * 2013-03-12 2014-10-09 Sangamo Biosciences, Inc. Methods and compositions for modification of hla

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574205A (en) * 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US6849612B2 (en) * 1993-01-21 2005-02-01 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
DE69233010T2 (de) * 1991-07-15 2004-02-19 Oklahoma Medical Research Foundation, Oklahoma Universale spenderzellen
US5602307A (en) * 1992-08-12 1997-02-11 Baylor College Of Medicine Non-human animal having predefined allele of a cellular adhesion gene
JPH06319585A (ja) * 1992-11-26 1994-11-22 Fujisawa Pharmaceut Co Ltd 抗体およびその製造法
JPH09512021A (ja) * 1994-04-19 1997-12-02 ザ ユニバーシティ オブ カンサス Ｉｃａｍ−１／ｌｆａ−１ 短鎖ペプチドおよび該ペプチドの使用方法
US6939712B1 (en) * 1998-12-29 2005-09-06 Impedagen, Llc Muting gene activity using a transgenic nucleic acid
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
JP2002542200A (ja) * 1999-04-21 2002-12-10 久光製薬株式会社 免疫寛容を誘発するｄ型ポリペプチドおよびその使用方法
US6399384B1 (en) * 1999-09-17 2002-06-04 Reneuron Limited Conditional immortalization of cells
DE10049549A1 (de) * 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
JP2008542252A (ja) * 2005-05-26 2008-11-27 インターサイテックス リミティド 同種真皮繊維芽細胞を用いる組織修復
US8247370B2 (en) * 2006-12-04 2012-08-21 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
AR080219A1 (es) * 2010-02-18 2012-03-21 Osiris Therapeutics Inc Productos de membranas corionicas inmunocompatibles
EP3229586B1 (en) * 2014-12-10 2025-07-30 Regents of the University of Minnesota Genetically modified cells, tissues, and organs for treating disease
AU2016206870B2 (en) * 2015-01-12 2022-02-17 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
CN104611370A (zh) * 2015-01-16 2015-05-13 深圳市科晖瑞生物医药有限公司 一种剔除β2-微球蛋白基因片段的方法
CA2988854A1 (en) * 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods
KR102796744B1 (ko) * 2015-06-09 2025-04-15 에디타스 메디신, 인코포레이티드 이식의 개선을 위한 crispr/cas-관련 방법 및 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165177A1 (en) * 2013-03-12 2014-10-09 Sangamo Biosciences, Inc. Methods and compositions for modification of hla

Also Published As

Publication number Publication date
EP3894546A1 (en) 2021-10-20
EP3894546A4 (en) 2022-12-21
WO2020131717A1 (en) 2020-06-25
US20220025332A1 (en) 2022-01-27
CA3123408A1 (en) 2020-06-25
JP2024041867A (ja) 2024-03-27
JP2022513490A (ja) 2022-02-08
AU2019403057A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
KR20200016954A (ko) 전신 면역억제가 불필요한 동종 이식편 내성
JP2021514665A (ja) がんおよび感染症を処置するための治療用細胞系および方法
JP5805089B2 (ja) 細胞集団の製造方法
BR112016028644B1 (pt) Método in vitro ou ex vivo para fabricar células t, composição compreendendo um agente de crioproteção e uma população de células efetoras imunes e usos terapêuticos dadita composição
US7767202B2 (en) Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules
CA3160113A1 (en) Generation of engineered regulatory t cells
US20140242039A1 (en) Adherent cells from adipose or placenta tissues and use thereof in therapy
EA012520B1 (ru) Способ получения цитотоксических лимфоцитов
JP2024041867A (ja) 遺伝子編集線維芽細胞の治療的使用
CN113544279A (zh) 包含芳基硫酸酯酶a的重组载体及其在用于治疗异染性脑白质营养不良的干细胞治疗中的用途
JP5485139B2 (ja) 遺伝子導入細胞の製造方法
US20250375520A1 (en) Production of immune cells
EP4488364A1 (en) Low immunogenic stem cells, low immunogenic cells differentiated or derived from stem cells, and production method therefor
Surbek et al. Perinatal stem-cell and gene therapy for hemoglobinopathies
JP2003531816A (ja) 遺伝子導入産物に機能的寛容を誘導する方法
Candotti The potential for therapy of immune disorders with gene therapy
US20040131599A1 (en) Fas ligand expressing hematopoietic cells for transplantation
Kennedy et al. Effect of ex vivo culture of CD34+ bone marrow cells on immune reconstitution of XSCID dogs following allogeneic bone marrow transplantation
Candotti Gene therapy for immunodeficiency
Almeida-Porada et al. Prenatal cell-and gene-based therapies for regenerative medicine
Lesniak et al. Targeted gene therapy to antigen-presenting cells in the central nervous system using hematopoietic stem cells
JP2023099685A (ja) 養子免疫療法における腫瘍フレアを管理する方法
WO2026068582A1 (en) Means and methods for modulating immune responses
WO2024243525A1 (en) Compositions, systems, and methods for combinatorial therapies containing fucosylated cells and chemokines and/or scaffolds for autoimmune conditions and regenerative medicine
CA2310016A1 (en) Genetically-modified myogenic progenitors and their use in cell and gene therapy

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SPINALCYTE LLC

Free format text: FORMER APPLICANT(S): FIGENE, LLC